Regeneron's EYLEA HD Approval Has an Asterisk – Growth Not Assured

What happened

Regeneron secured a label expansion for EYLEA HD in November 2025, adding RVO and monthly dosing flexibility, which initially buoyed sentiment. However, the Fool article characterizes the approval as having an asterisk, reflecting lingering concerns over manufacturing delays for the pre-filled syringe and the uncertain pace of share gains against Roche's Vabysmo. DeepValue's analysis confirms that while Q4 2025 showed 18% Q/Q sales growth and share gains, the overall anti-VEGF category is under pressure from biosimilars and compounded bevacizumab. The company's own filing states there is 'no assurance' that EYLEA HD will offset the decline of EYLEA 2mg, and the key catalyst—FDA decision on the pre-filled syringe in Q2 2026—remains a critical execution risk. Investors are thus left with a positive but conditional outlook where franchise stabilization is not guaranteed.

Implication

Investors should view the EYLEA HD label expansion as a necessary but insufficient condition for franchise stabilization. The real test lies in the Q2 2026 FDA decision on the pre-filled syringe, which could reduce office friction and drive adoption. If it slips or fails, the competitive edge against Roche and biosimilars weakens. Meanwhile, Dupixent profit-share provides a backstop, but the top-line concentration in EYLEA means that any sequential decline in total franchise dollars would pressure the stock. The DeepValue base case of $830 assumes moderate HD growth, but the 'asterisk' suggests that optimism is not fully priced in. For now, the risk/reward is balanced: the stock at $774 offers upside if catalysts hit, but downside to the $620 bear case if they miss.

Thesis delta

The thesis shifts from a straightforward approval catalyst to a conditional one: the label expansion is a positive but insufficient step. The key delta is the pre-filled syringe approval—without it, EYLEA HD adoption may plateau, failing to offset 2mg erosion. Thus, the near-term conviction hinges on regulatory and operational execution, not just label flexibility.